Get the latest news, insights, and market updates on HUMA (Humacyte, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Why Humacyte (HUMA) Is Rising After Positive Phase 3 Results in High-Risk Hemodialysis Patients
Humacyte recently presented positive two-year results from its Phase 3 V007 clinical trial, showing that its acellular tissue engineered vessel (ATEV) provided superior duration of use in high-need hemodialysis subgroups, such as female, obese, and diabetic patients, compared to the standard autogenous fistula. A particularly important insight from the study is that the ATEV offered a comparable safety profile to the current gold standard while significantly extending average access duration... Nov 12, 2025 - $HUMA
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer to planned BLA filing in dialysis and first-in-human studies in cardiac bypass graft surgery – – IND submitted to the FDA for the CABG indication – - Symvess™ and pipeline programs highlighted in multiple scientific publications and presentations - - Conference call today at 8:00 am ET - DURHAM, N.C., Nov 12, 2025 - $HUMA
Humacyte (HUMA): Evaluating Valuation Following Promising Phase 3 V007 Results in Hemodialysis Access
Humacyte (HUMA) just shared new two-year results from its V007 Phase 3 study at Kidney Week 2025. The ATEV device performed better than traditional AV fistulas for hemodialysis access, particularly in challenging patient groups. See our latest analysis for Humacyte. Humacyte’s series of positive data releases have yet to spark a turnaround in its share price, as a tough market environment continues to weigh heavily. Since the start of the year, the stock’s share price is down around 74... Nov 11, 2025 - $HUMA
Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology’s Kidney Week 2025
– The ATEV™ was observed to have superior duration of use over 24 months compared to autogenous fistula in high-need subgroups with historically poor outcomes with AV fistula procedures – – The significantly longer duration of ATEV use in these high-need patients could greatly reduce reliance on catheters for dialysis access, a major cause of complications, morbidity and cost in dialysis patients – DURHAM, N.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage Nov 10, 2025 - $HUMA
Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update. Title:Humacyte Third Quarter 2025 Financial Results and Corporate U Nov 6, 2025 - $HUMA
Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma
- Results published in AAST’s Trauma Surgery & Acute Care Open Journal - - Study compared outcomes of patients treated with Symvess with patients in PROOVIT registry who were treated with vein - - In a comparison to prior results in the PROOVIT registry, outcomes for Symvess and autologous vein were similar for treatment of vascular trauma - DURHAM, N.C., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally impl Oct 30, 2025 - $HUMA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple